S&P 500   4,027.81 (+1.42%)
DOW   32,717.60 (+1.00%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
S&P 500   4,027.81 (+1.42%)
DOW   32,717.60 (+1.00%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
S&P 500   4,027.81 (+1.42%)
DOW   32,717.60 (+1.00%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
S&P 500   4,027.81 (+1.42%)
DOW   32,717.60 (+1.00%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
NYSE:ABBV

AbbVie - ABBV Competitors

$158.00
-0.25 (-0.16%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$156.36
$159.70
50-Day Range
$144.61
$158.25
52-Week Range
$134.09
$175.91
Volume
3.92 million shs
Average Volume
6.41 million shs
Market Capitalization
$278.73 billion
P/E Ratio
23.90
Dividend Yield
3.75%
Price Target
$161.12

ABBV vs. MRK, LLY, PFE, JNJ, BMY, ZTS, NVO, AZN, NVS, and ABT

Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Merck & Co., Inc. (MRK), Eli Lilly and (LLY), Pfizer (PFE), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), and Abbott Laboratories (ABT). These companies are all part of the "pharmaceutical preparations" industry.

AbbVie vs.

Merck & Co., Inc. (NYSE:MRK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Merck & Co., Inc. currently has a consensus price target of $119.35, suggesting a potential upside of 13.94%. AbbVie has a consensus price target of $161.12, suggesting a potential upside of 2.58%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts plainly believe Merck & Co., Inc. is more favorable than AbbVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merck & Co., Inc.
0 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.71
AbbVie
0 Sell rating(s)
9 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.44

AbbVie received 352 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 73.39% of users gave AbbVie an outperform vote while only 66.81% of users gave Merck & Co., Inc. an outperform vote.

CompanyUnderperformOutperform
Merck & Co., Inc.Outperform Votes
928
66.81%
Underperform Votes
461
33.19%
AbbVieOutperform Votes
1280
73.39%
Underperform Votes
464
26.61%

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 67.7% of AbbVie shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Merck & Co., Inc. has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Merck & Co., Inc. has higher revenue and earnings than AbbVie. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$59.28 billion4.49$14.52 billion$5.7118.35
AbbVie$58.05 billion4.77$11.84 billion$6.6123.76

In the previous week, AbbVie had 4 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 16 mentions for AbbVie and 12 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 1.03 beat AbbVie's score of 0.29 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merck & Co., Inc.
9 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
8 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Merck & Co., Inc. pays an annual dividend of $2.92 per share and has a dividend yield of 2.8%. AbbVie pays an annual dividend of $5.92 per share and has a dividend yield of 3.8%. Merck & Co., Inc. pays out 51.1% of its earnings in the form of a dividend. AbbVie pays out 89.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 12 consecutive years and AbbVie has raised its dividend for 51 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Merck & Co., Inc. has a net margin of 24.49% compared to AbbVie's net margin of 20.39%. AbbVie's return on equity of 154.52% beat Merck & Co., Inc.'s return on equity.

Company Net Margins Return on Equity Return on Assets
Merck & Co., Inc. 24.49% 43.47% 17.68%
AbbVie 20.39% 154.52% 17.54%

Summary

Merck & Co., Inc. beats AbbVie on 11 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABBV vs. The Competition

MetricAbbViePharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$277.08B$5.59B$4.34B$14.40B
Dividend Yield3.75%2.62%2.42%3.92%
P/E Ratio23.764.85104.3219.72
Price / Sales4.77282.223,533.0510.82
Price / Cash8.4518.0119.6516.41
Price / Book16.064.264.536.81
Net Income$11.84B$187.05M$114.97M$867.49M
7 Day Performance2.21%1.22%0.97%2.14%
1 Month Performance2.05%-8.37%-6.73%-5.60%
1 Year Performance-3.16%-11.92%-15.59%-14.72%

AbbVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRK
Merck & Co., Inc.
3.2309 of 5 stars
$104.40
-1.1%
$119.35
+14.3%
+29.9%$265.03B$59.28B18.2869,000Analyst Downgrade
Positive News
LLY
Eli Lilly and
3.0877 of 5 stars
$330.97
0.0%
$382.05
+15.4%
+15.8%$314.52B$28.54B47.9739,000Insider Selling
Short Interest ↑
PFE
Pfizer
3.6962 of 5 stars
$40.01
-1.6%
$50.38
+25.9%
-24.9%$225.83B$100.33B7.3083,000
JNJ
Johnson & Johnson
2.9769 of 5 stars
$151.05
-1.8%
$174.73
+15.7%
-14.6%$393.38B$94.94B22.41155,800Analyst Report
Short Interest ↑
BMY
Bristol-Myers Squibb
2.8885 of 5 stars
$67.24
-0.4%
$79.69
+18.5%
-6.7%$141.12B$46.16B22.7934,300Short Interest ↑
Positive News
ZTS
Zoetis
2.5547 of 5 stars
$161.38
-2.9%
$223.83
+38.7%
-12.8%$74.78B$8.08B35.8613,800Analyst Revision
NVO
Novo Nordisk A/S
2.5997 of 5 stars
$146.69
-0.4%
$697.78
+375.7%
+43.9%$331.96B$25.06B42.2755,185Short Interest ↑
Positive News
AZN
AstraZeneca
2.4729 of 5 stars
$66.57
-0.6%
$126.00
+89.3%
+4.9%$206.35B$44.35B62.2283,500Short Interest ↓
NVS
Novartis
1.8012 of 5 stars
$81.96
-2.0%
$82.63
+0.8%
+4.6%$181.34B$50.55B25.85101,703Analyst Upgrade
ABT
Abbott Laboratories
3.3947 of 5 stars
$96.86
-1.5%
$124.67
+28.7%
-19.1%$168.34B$43.65B24.77115,000Analyst Report
Short Interest ↓
This page (NYSE:ABBV) was last updated on 3/29/2023 by MarketBeat.com Staff